IP Library Granted Patent US 11,426,435
Granted Patent B2
US 11,426,435 · App. 17/681,529 · Granted Aug 30, 2022

Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Inventor: Thomas J. Borody (Five Dock, AU)
Assignee: Finch Therapeutics Holdings LLC
A61K35/74A61K9/4891A61K35/24A61K35/742A61P1/12C12N1/00C12N1/20A61B10/0038A61K9/4875A61K2035/115A61M5/142A61M31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,435
App. No.
17/681,529
Granted
Aug 30, 2022
Kind
B2
Abstract

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, for inducing the purgation of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual. The invention also provides devices for delivering a fecal material to a patient.

Claims (30)

1. A method of manufacturing a stool composition comprising viable fecal bacteria from a stool of a healthy human donor, while limiting damage of the fecal bacteria during the manufacture and storage of the stool composition, the method comprising:

obtaining the stool from the healthy human donor;

storing the stool as non-frozen stool prior to processing the stool at a centralized flora bank;

processing the stool at the centralized flora bank by adding a cryoprotectant to the stool and homogenizing the stool and the cryoprotectant to form the stool composition; and

incorporating the stool composition into a container for storage and transport of the stool composition to a location distant from the centralized flora bank;

wherein the method preserves a number of viable bacteria from the stool sufficient to overcome a Clostridium difficile infection in a patient following administration of the stool composition to the patient.

2. The method of claim 1 , wherein the container comprises an oxygen-resistant plastic.

3. The method of claim 1 , wherein the container is made of aluminum-metallized polyethylene terephthalate polyester film.

4. The method of claim 1 , wherein the centralized flora bank comprises stools obtained from multiple healthy human donors.

5. The method of claim 1 , wherein the obtaining comprises collecting the stool in an anaerobic container and maintaining it at a temperature below room temperature but above freezing before storing.

6. The method of claim 1 , wherein the obtaining comprises collecting the stool in an anaerobic container comprising one or more substances that adsorb or absorb oxygen.

7. The method of claim 1 , wherein the cryoprotectant is glycerol.

8. The method of claim 1 , wherein the processing further comprises adding one or more antioxidants to the stool.

9. The method of claim 1 , wherein the processing comprises screening the stool for pathogens.

10. The method of claim 1 , wherein the container comprises a bag capable of holding fluids with one or more ports for entry or exit of fluids.

11. The method of claim 1 , wherein the transport is carried out in conditions below room temperature but above freezing.

12. The method of claim 1 , wherein the container is operably connected to a tubing equipment.

13. The method of claim 12 , wherein the container is attached to a pump with a one-way valve through the tubing equipment.

14. A method of manufacturing a standardized stool composition comprising viable fecal bacteria from a stool of a healthy human donor, while limiting damage of the fecal bacteria during the manufacture and storage of the standardized stool composition, the method comprising:

obtaining the stool from the healthy human donor;

storing the stool as non-frozen stool prior to processing the stool at a centralized flora bank;

processing the stool at the centralized flora bank by adding a cryoprotectant to the stool and homogenizing the stool and the cryoprotectant to form a standardized stool composition; and

incorporating the standardized stool composition into a container for storage and transport of the standardized stool composition to a location distant from the centralized flora bank;

wherein the standardized stool composition comprises sufficient viable bacteria from the stool to restore deficient fecal flora in a patient with a Clostridium difficile infection following administration of the standardized stool composition to the patient.

15. The method of claim 14 , wherein the container comprises an oxygen-resistant plastic.

16. The method of claim 14 , wherein the obtaining comprises collecting the stool in an anaerobic container and maintaining it at a temperature below room temperature but above freezing until it arrives at the centralized flora blank.

17. The method of claim 16 , wherein the anaerobic container comprises one or more substances that adsorb or absorb oxygen.

18. The method of claim 16 , wherein the anaerobic container is filled with nitrogen.

19. The method of claim 16 , wherein the anaerobic container is filled with a gas that will not damage fecal bacteria in the stool.

20. The method of claim 16 , wherein the anaerobic container is configured to not leak any gas.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2022
From: BORODY, THOMAS J.
To: CRESTOVO HOLDINGS, LLC
Reel/Frame 059901/0377 →
CHANGE OF NAME Recorded May 13, 2022
From: CRESTOVO HOLDINGS, LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 060065/0557 →
Priority Claims (1)
AU 2010903474 · Aug 4, 2010 · national
Continuity (15)
Continuation 17496398 · Oct 7, 2021
Continuation 16523726 · Jul 26, 2019
Continuation 16433437 · Jun 6, 2019
Continuation 16364144 · Mar 25, 2019
Continuation 16118400 · Aug 30, 2018
Continuation 15975456 · May 9, 2018
Continuation 15950939 · Apr 11, 2018
Continuation 15782519 · Oct 12, 2017
Continuation 15093679 · Apr 7, 2016
Continuation 13813915
Provisional Application 61494363 · Jun 7, 2011
Provisional Application 61483487 · May 6, 2011
Provisional Application 61451087 · Mar 9, 2011
Provisional Application 61450099 · Mar 7, 2011
Related Publication 20220175853A1 · Jun 9, 2022